Literature DB >> 6094961

Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors.

J D Sato, T Kawamoto, A D Le, J Mendelsohn, J Polikoff, G H Sato.   

Abstract

Four mouse hybridomas secreting monoclonal immunoglobulin G (IgG) antibodies to epidermal growth factor (EGF) receptors of A431 cells were obtained independently from four fusion experiments. Three of the antibodies, 528 IgG, 225 IgG, and 579 IgG, inhibited the binding of [125I]EGF to A431 cells by at least 95%, and they competed with each other for binding to A431 cells. These antibodies bound to A431 cells, HeLa-S cells and human foreskin fibroblasts with dissociation constants in the range of Kd = 0.6 X 10(-9) to 2.5 X 10(-9) M. The fourth monoclonal antibody, 455 IgG, bound to A431 cells with lower affinity (Kd = 2.0 X 10(-8) M), and it had no effect on the binding of either EGF or the other antibodies to A431 cells. All four antibodies immunoprecipitated EGF receptors from Triton X-100 extracts of A431 membranes, but they were unable to bind to three rodent cell lines. In biological assays, none of the antibodies was able to mimic EGF. The antibodies which inhibited the binding of EGF blocked EGF-enhanced phosphorylation of A431 membrane proteins and inhibited EGF induced human fibroblast proliferation. These three antagonistic antibodies also partially reversed the inhibition of A431 growth by EGF. In contrast, 455 IgG had no effect on the early or delayed cellular responses to EGF.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6094961

Source DB:  PubMed          Journal:  Mol Biol Med        ISSN: 0735-1313


  129 in total

1.  Interrupting autocrine ligand-receptor binding: comparison between receptor blockers and ligand decoys.

Authors:  K E Forsten; D A Lauffenburger
Journal:  Biophys J       Date:  1992-09       Impact factor: 4.033

Review 2.  Monoclonal antibodies to epidermal growth factor receptors in studies of receptor structure and function.

Authors:  T Kawamoto; G H Sato; K Takahashi; M Nishi; S Taniguchi; J D Sato
Journal:  Cytotechnology       Date:  1990-05       Impact factor: 2.058

Review 3.  The ERBB network: at last, cancer therapy meets systems biology.

Authors:  Yosef Yarden; Gur Pines
Journal:  Nat Rev Cancer       Date:  2012-07-12       Impact factor: 60.716

Review 4.  Understanding resistance to EGFR inhibitors-impact on future treatment strategies.

Authors:  Deric L Wheeler; Emily F Dunn; Paul M Harari
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

Review 5.  The ErbB receptors as targets for breast cancer therapy.

Authors:  J Albanell; J Baselga
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

Review 6.  ErbB receptors: from oncogenes to targeted cancer therapies.

Authors:  Hongtao Zhang; Alan Berezov; Qiang Wang; Geng Zhang; Jeffrey Drebin; Ramachandran Murali; Mark I Greene
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

7.  Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against the EGF receptor on four glioma cell lines.

Authors:  M H Werner; P A Humphrey; D D Bigner; S H Bigner
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

8.  Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells.

Authors:  Emily J Faivre; Carol A Lange
Journal:  Mol Cell Biol       Date:  2006-10-30       Impact factor: 4.272

9.  Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin.

Authors:  X Wu; Z Fan; H Masui; N Rosen; J Mendelsohn
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

Review 10.  Interaction of antibodies with ErbB receptor extracellular regions.

Authors:  Karl R Schmitz; Kathryn M Ferguson
Journal:  Exp Cell Res       Date:  2008-10-22       Impact factor: 3.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.